HEALTHIER CHINA THROUGH INNOVATION

Under the China Association of Enterprises with Foreign Investment (CAEFI), the R&D-based Pharmaceutical Association Committee (RDPAC) is a non-profit organization made up of 45 member companies with pharmaceutical R&D capability.


RDPAC Code of Practice

November 17, 2022
A major requisite for innovation is integrity, which is also the foundation of reputation. Without ethical decision-making, there is no true innovation.

RDPAC Announces Membership Succession of Executive Committee 2022-2023

May 25, 2022
The R&D-based Pharmaceutical Association Committee (RDPAC) has announced a change in membership of the RDPAC Executive Committee 2022-2023.

Paying for Innovation to Secure Payback - To Build a Value-oriented Innovative Payment System

April 22, 2022
The 2022 Jinling Pharmoeconomics Forum and the Annual Conference of Pharmoeconomics Committee, Jiangsu Pharmaceutical Association were held online on April 16-17.

PUBLICATIONS

DEEPENING THE DRUG INNOVATION ECOSYSTEM REFORM – A PLAN TO DESIGN AND BUILD CHINA’S CLINICAL RESEARCH SYSTEM

Health is the common aspiration of all mankind, and a healthy China constitutes an integral part of the “China Dream”.